Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | METAP1 | P53582 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CBFB | Q13951 | 9/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM6B | O15054 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11034496 | 0.91 | METAP1 (0.58) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL5635897 | 0.90 | CHEK2 (0.66) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL19970726 | 0.89 | F2 (0.70) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL29517866 | 0.88 | CHEK2 (0.67) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL179156 | 0.88 | CHEK2 (0.67) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL29882822 | 0.85 | CBFB (0.55) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL32660751 | 0.85 | CBFB (0.55) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL28938259 | 0.85 | CBFB (0.55) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL4245430 | 0.85 | CBFB (0.55) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 | |
| SCHEMBL18365268 | 0.84 | METAP2 (0.59) | METAP2NPC1RAB9AMETAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863771-B1 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-11-07 | — | — | EP | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-4678234-A1 | ANTAGONIST HETEROCYCLIC COMPOUNDS INVOLVED IN THE CGAS-STING ROUTE | Centre National de la Recherche Scientifique (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3670509-A1 | INHIBITORS OF INV(16) LEUKEMIA | The University of Virginia Patent Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3512838-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | Centre National De La Recherche Scientifique (FR) | 2019-07-24 | — | — | EP | disclosed |
| US-10138245-B2 | Fused triazole derivatives as phosphodiesterase 10A inhibitors | CELON PHARMA S.A. (PL) | 2018-11-27 | — | — | US | disclosed |
| EP-2212282-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | METAP2 4104/4885NPC1 1156/4885RAB9A 3131/4885 |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | METAP2 2759/4885NPC1 1047/4885RAB9A 3245/4885 |
| US-10138245-B2 | Fused triazole derivatives as phosphodiesterase 10A inhibitors | PDE3B, PDE3A, PDE5A | METAP2 3431/4885NPC1 3274/4885RAB9A 285/4885 |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | METAP2 341/4885NPC1 188/4885RAB9A 2719/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | METAP2 4282/4885NPC1 3614/4885RAB9A 3902/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | METAP2 4554/4885NPC1 715/4885RAB9A 1738/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | METAP2 341/4885NPC1 188/4885RAB9A 2719/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | METAP2 4104/4885NPC1 1156/4885RAB9A 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.